A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

January 31, 2027

Conditions
OSAOverweight or Obesity
Interventions
DRUG

Orforglipron

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (66)

333

Chang Gung Medical Foundation-Linkou Branch, Taoyuan District

600

Chiayi Christian Hospital, Chiayi City

704

National Cheng Kung University Hospital, Tainan City

2000

INECO Neurociencias Oroño, Rosario

3100

Centro Privado de Medicina Respiratoria, Paraná

10117

Advanced Sleep Research, Berlin

11650

Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares, Mexico City

14900

Milan Kvapil s.r.o., Diabetologicka ambulance, Prague

15236

Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18), Pittsburgh

15401

Preferred Primary Care Physicians, Uniontown

21200

Centro de Investigacion en Artritis y Osteoporosis SC, Mexicali

23758

RED-Institut GmbH, Oldenburg

28401

Accellacare - Wilmington, Wilmington

30078

EBGS Clinical Research Center, Snellville

30449

Siteworks GmbH - Hannover, Hanover

31110

Enclifar Ensayos Clínicos Farmacológicos Sc, Chihuahua City

44130

Diseno y Planeacion en Investigacion Medica, Guadalajara

44670

Private Practice - Dr. Arechavaleta Granell Maria del Rosario, Guadalajara

45136

InnoDiab Forschung Gmbh, Essen

45212

CTI Clinical Research Center, Cincinnati

45359

Unterfrintroper Hausarztzentrum Klinische Forschung, Essen

48145

Institut für Diabetesforschung GmbH Münster, Münster

64020

CEINV Salud, Monterrey

71105

Care Access - Shreveport, Shreveport

75028

Prime Revival Research Institute, LLC, Flower Mound

76137

Siteworks - Karlsruhe, Karlsruhe

78731

FutureSearch Trials of Neurology, Austin

80012

Care Access - Aurora, Aurora

83221

Elite Clinical Trials, Blackfoot

87107

The Sleep Spot - Maimonides, Albuquerque

90274

Peninsula Research Associates, Rolling Hills Estates

90815

Ark Clinical Research, Long Beach

92103

Artemis Institute for Clinical Research, San Diego

96049

CIMS Studienzentrum Bamberg, Bamberg

98007

Northwest Clinical Research Center, Bellevue

100034

Peking University People's Hospital, Beijing

130021

The First Hospital of Jilin University, Changchun

150001

The Fourth Affiliated Hospital of Harbin Medical University, Harbin

201200

Pudong New Area People's Hospital Shanghai, Shanghai

214023

Wuxi People's Hospital, Wuxi

313000

Huzhou Central Hospital, Huzhou

315010

Ningbo First Hospital, Ningbo

330006

Jiangxi Provincial People's Hospital, Nanchang

404332

China Medical University Hospital, Taichung

471003

The First Affiliated Hospital of Henan University of Science &Technology, Luoyang Shi

518020

ShenZhen People's Hospital, Shenzhen

610072

Sichuan Provincial People's Hospital, Chengdu

C1056ABI

Centro de Investigaciones Metabólicas (CINME), Buenos Aires

C1120AAC

Centro Médico Viamonte, Buenos Aires

C1405BUB

Consultorio de Investigación Clínica EMO SRL, Buenos Aires

C1425AGC

Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada, Buenos Aires

X5800AEV

Instituto Médico Río Cuarto, Río Cuarto

L6300

Centro de Salud e Investigaciones Médicas, Santa Rosa

90430-001

Núcleo de Pesquisa Clínica do Rio Grande do Sul, Porto Alegre

01228-000

CPQuali Pesquisa Clínica, São Paulo

01236030

BR Trials - Ensaios Clinicos e Consultoria, São Paulo

04266-010

CEPIC - Centro Paulista de Investigação Clínica, São Paulo

05403-000

Hospital das Clinicas FMUSP, São Paulo

256 01

Nemocnice Rudolfa a Stefanie Benešov, Benešov

150 00

Praglandia s.r.o, Prague

802-0052

Kirigaokatsuda Hospital, Kitakyushu

532-0003

Osaka Kaisei Hospital, Osaka

593-8304

Sakai City Medical Center, Sakai

901-2132

Nakamura Clinic, Urasoe

222-0033

RESM Respiratory and Sleep Medical Care Clinic, Yokohama

03100

RM Pharma Specialists - Unidad Especializada en Datos, Mexico City

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06649045 - A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | Biotech Hunter | Biotech Hunter